Led Leadingtac Pharmaceutical's RMB 200M+ (~$28M) Series B financing for its targeted protein degradation (TPD) drug pipeline, with Partner Dr. Lin Kan representing the firm.
Leadingtac Pharmaceutical is a preclinical-stage biopharmaceutical company focused on developing first-in-class and best-in-class small molecule innovative drugs, particularly in the field of targeted protein degradation (TPD) for autoimmune diseases and oncology
Leadingtac Pharmaceutical is a preclinical-stage biopharmaceutical company focused on developing first-in-class and best-in-class small molecule innovative drugs, particularly in the field of targeted protein degradation (TPD) for autoimmune diseases and oncology.